Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI learns to spot Crohn's on MRI in new pilot study

NCT ID NCT03706664

Knowledge-focused Sponsor: London North West Healthcare NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study is testing whether a deep learning algorithm can identify and score inflamed segments of the terminal ileum in MRI scans of people with Crohn's disease. Researchers will use 226 anonymized MRI scans, with radiologists first marking normal and abnormal areas. The algorithm's performance will be compared to the radiologists' labels. If it works, the algorithm could eventually help speed up and improve the accuracy of Crohn's diagnosis and monitoring.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
machine learning algorithm
What this could lead to
If successful, this could lead to a tool that helps radiologists diagnose and monitor Crohn's disease more quickly and accurately.
What could go wrong
This is an early pilot study with only 226 patients. The algorithm may not work as well in real-world settings or on different types of MRI machines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 226 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2019

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for all cases: * Patient's age \>16 years of age, (this age cut off has been used in the recent METRIC trial investigating imaging in Crohn's disease) * MRI sequences obtained include axial T2 weighted images; coronal T2 weighted images and axial post contrast MRI images. Inclusion criteria for normal MR Enterography cases: • Normal MR Enterography studies reviewed in consensus by two Radiologists (UP \& PL). Normal is defined as no sites of small or large bowel Crohn's disease. Inclusion criteria for terminal ileal Crohn's cases: * MR Enterography studies reviewed in consensus by two Radiologists shows terminal ileal Crohn's disease. Patients with more than one segment of small bowel Crohn's disease including terminal ileum are eligible. Patients with terminal ileal Crohn's disease continuous with large bowel are eligible. * Diagnosis of Crohn's disease of terminal ileum based on endoscopic, histological and radiological findings. (This criteria has been used in the recent METRIC trial investigating imaging in Crohn's disease). Exclusion Criteria for all cases: * Poor quality MRI images as judged by consensus Radiologist opinion. * No more than 3 MRI scans will come from the same patient. Exclusion criteria for terminal ileal Crohn's cases: * MR Enterography shows any bowel abnormality not due to Crohn's. * Patient has undergone previous small or large bowel resection (this will distort anatomy and is beyond the scope of the present project). Patients' with other previous surgeries are eligible. * Patients with large bowel Crohn's disease not continuous with the terminal ileum.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crohn disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Crohn disease

Contacts and locations

Locations

  • St Mark's Hospital

    London, Harrow, HA13UJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.